174 related articles for article (PubMed ID: 36776544)
1. The Role of C-Reactive Protein in the Prognosis of Prostate Cancer: A Meta-Analysis.
Liu T; Zhuo L
J Environ Public Health; 2023; 2023():6222324. PubMed ID: 36776544
[TBL] [Abstract][Full Text] [Related]
2. C-reactive protein levels could be a prognosis predictor of prostate cancer: A meta-analysis.
Zhou K; Li C; Chen T; Zhang X; Ma B
Front Endocrinol (Lausanne); 2023; 14():1111277. PubMed ID: 36817592
[TBL] [Abstract][Full Text] [Related]
3. C-reactive Protein Is a Predictor of Prognosis of Prostate Cancer: A Systematic Review and Meta-Analysis.
Liao DW; Hu X; Wang Y; Yang ZQ; Li X
Ann Clin Lab Sci; 2020 Mar; 50(2):161-171. PubMed ID: 32366552
[TBL] [Abstract][Full Text] [Related]
4. Prognostic role of C-reactive protein in prostate cancer: a systematic review and meta-analysis.
Liu ZQ; Chu L; Fang JM; Zhang X; Zhao HX; Chen YJ; Xu Q
Asian J Androl; 2014; 16(3):467-71. PubMed ID: 24589465
[TBL] [Abstract][Full Text] [Related]
5. The elevated C-reactive protein level is associated with poor prognosis in prostate cancer patients treated with radiotherapy.
Thurner EM; Krenn-Pilko S; Langsenlehner U; Stojakovic T; Pichler M; Gerger A; Kapp KS; Langsenlehner T
Eur J Cancer; 2015 Mar; 51(5):610-9. PubMed ID: 25618827
[TBL] [Abstract][Full Text] [Related]
6. Pooled Analysis of C-Reactive Protein Levels and Mortality in Prostate Cancer Patients.
Graff JN; Beer TM; Liu B; Sonpavde G; Taioli E
Clin Genitourin Cancer; 2015 Aug; 13(4):e217-e221. PubMed ID: 25735198
[TBL] [Abstract][Full Text] [Related]
7. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
8. Clinical association of metabolic syndrome, C-reactive protein and testosterone levels with clinically significant prostate cancer.
Gómez-Gómez E; Carrasco-Valiente J; Campos-Hernández JP; Blanca-Pedregosa AM; Jiménez-Vacas JM; Ruiz-García J; Valero-Rosa J; Luque RM; Requena-Tapia MJ
J Cell Mol Med; 2019 Feb; 23(2):934-942. PubMed ID: 30450757
[TBL] [Abstract][Full Text] [Related]
9. Serum amyloid A, phospholipase A₂-IIA and C-reactive protein as inflammatory biomarkers for prostate diseases.
Menschikowski M; Hagelgans A; Fuessel S; Mareninova OA; Asatryan L; Wirth MP; Siegert G
Inflamm Res; 2013 Dec; 62(12):1063-72. PubMed ID: 24061501
[TBL] [Abstract][Full Text] [Related]
10. The association between C-reactive protein (CRP) level and biochemical failure-free survival in patients after radiation therapy for nonmetastatic adenocarcinoma of the prostate.
Hall WA; Nickleach DC; Master VA; Prabhu RS; Rossi PJ; Godette K; Cooper S; Jani AB
Cancer; 2013 Sep; 119(18):3272-9. PubMed ID: 23818401
[TBL] [Abstract][Full Text] [Related]
11. C-reactive protein is a predictor of prognosis in renal cell carcinoma patients receiving tyrosine kinase inhibitors: A meta-analysis.
Wang Z; Peng S; Wang A; Xie H; Guo L; Jiang N; Niu Y
Clin Chim Acta; 2017 Dec; 475():178-187. PubMed ID: 29080691
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of C-reactive protein in urological cancers: a systematic review and meta-analysis.
Dai J; Tang K; Xiao W; Yu G; Zeng J; Li W; Zhang YQ; Xu H; Chen ZQ; Ye ZQ
Asian Pac J Cancer Prev; 2014; 15(8):3369-75. PubMed ID: 24870724
[TBL] [Abstract][Full Text] [Related]
13. Efficiency of C-reactive protein in prognosis evaluation of prostate cancer: a systematic review and meta-analysis.
Du J; Lan J; Xiong J; Yang H; Xu X; Tang C; Huang G; Ying Q; Mu J; Hu Q
Transl Cancer Res; 2021 Oct; 10(10):4432-4439. PubMed ID: 35116300
[TBL] [Abstract][Full Text] [Related]
14. Tumoral C-reactive protein and nuclear factor kappa-B expression are associated with clinical outcome in patients with prostate cancer.
McCall P; Catlow J; McArdle PA; McMillan DC; Edwards J
Cancer Biomark; 2011-2012; 10(2):91-9. PubMed ID: 22430136
[TBL] [Abstract][Full Text] [Related]
15. C-reactive protein, interleukin-6, and prostate cancer risk in men aged 65 years and older.
Pierce BL; Biggs ML; DeCambre M; Reiner AP; Li C; Fitzpatrick A; Carlson CS; Stanford JL; Austin MA
Cancer Causes Control; 2009 Sep; 20(7):1193-203. PubMed ID: 19267250
[TBL] [Abstract][Full Text] [Related]
16. The Predictive Potential of the Baseline C-Reactive Protein Levels for the Efficiency of Immune Checkpoint Inhibitors in Cancer Patients: A Systematic Review and Meta-Analysis.
Han CL; Meng GX; Ding ZN; Dong ZR; Chen ZQ; Hong JG; Yan LJ; Liu H; Tian BW; Yang LS; Xue JS; Li T
Front Immunol; 2022; 13():827788. PubMed ID: 35211122
[TBL] [Abstract][Full Text] [Related]
17. The prognostic role of C-reactive protein in patients with head and neck squamous cell carcinoma: A meta-analysis.
Chen Y; Cong R; Ji C; Ruan W
Cancer Med; 2020 Dec; 9(24):9541-9553. PubMed ID: 33201589
[TBL] [Abstract][Full Text] [Related]
18. Genetic variation across C-reactive protein and risk of prostate cancer.
Markt SC; Rider JR; Penney KL; Schumacher FR; Epstein MM; Fall K; Sesso HD; Stampfer MJ; Mucci LA
Prostate; 2014 Jul; 74(10):1034-42. PubMed ID: 24844401
[TBL] [Abstract][Full Text] [Related]
19. Circulating prediagnostic interleukin-6 and C-reactive protein and prostate cancer incidence and mortality.
Stark JR; Li H; Kraft P; Kurth T; Giovannucci EL; Stampfer MJ; Ma J; Mucci LA
Int J Cancer; 2009 Jun; 124(11):2683-9. PubMed ID: 19189403
[TBL] [Abstract][Full Text] [Related]
20. Simple stratification of survival using bone scan and serum C-reactive protein in prostate cancer patients with metastases.
Nakashima J; Kikuchi E; Miyajima A; Nakagawa K; Oya M; Ohigashi T; Murai M
Urol Int; 2008; 80(2):129-33. PubMed ID: 18362480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
